首页> 外文OA文献 >Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies

【2h】

Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies

机译：复发或难治性淋巴瘤患者的两种不同剂量和雷达肾上腺素丙种丙烯酸酯的两种不同剂量和雷达肾上腺素素的调度，揭开或难治性淋巴瘤的患者揭示了T细胞恶性肿瘤中标记的活性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Owen A. OConnor; Steven Horwitz; Paul Hamlin; Carol Portlock; Craig H. Moskowitz; Debra Sarasohn; Ellen Neylon; Jill Mastrella; Rachel Hamelers; Barbara MacGregor-Cortelli; Molly Patterson; Venkatraman E. Seshan; Frank Sirotnak; Martin Fleisher; Diane R. Mould; Mike Saunders; Andrew D. Zelenetz;
展开▼
作者单位

展开▼
年度 2009
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. [J] . OConnor OA, Horwitz S, Hamlin P Journal of Clinical Oncology . 2009,第26期

机译：在复发或难治性淋巴瘤患者中，对两种不同剂量和时间表的普拉拉特酯（一种减少叶酸载体的高亲和力底物）进行II-I-II期研究，发现其在T细胞恶性肿瘤中具有显着活性。
2. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma [J] . Amengual Jennifer E., Lichtenstein Renee, Lue Jennifer, Blood: The Journal of the American Society of Hematology . 2018,第4期

机译：romidepsin和ralatrexate的1阶段研究显示复发和难治性T细胞淋巴瘤的显着活性
3. 461 POSTER Early phase experience with pralatrexate (10-propargy l-10-deazaaminopterin [PRX]), a novel antifolate with high afnity forthe reduced folate carrier, in patients with chemotherapy refractory lymphoproliferative malignancies [J] . O.OConnor, E.Hamlin, E.Neylon, European Journal of Cancer Supplements . 2006,第12期

机译：461海报普雷西酯（10-propargy l-10-deazaaminopterin [PRX]）是一种新型的抗叶酸药物，对减少的叶酸载体具有高亲和力，可用于化疗难治性淋巴增生性恶性肿瘤患者
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate a High-Affinity Substrate for the Reduced Folate Carrier in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies [O] . Owen A. OConnor, Steven Horwitz, Paul Hamlin, -1

机译：II-I-II期研究两种不同剂量和方案的Pralatrexate（一种用于减少叶酸载体的高亲和力底物）在复发性或难治性淋巴瘤患者中显示T细胞恶性肿瘤的标记活性
6. A PHASE 1 STUDY OF PRALATREXATE PLUS ROMIDEPSIN REVEALS MARKED ACTIVITY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) PERIPHERAL T-CELL LYMPHOMA (PTCL) [O] . J.E. Amengual, R. Lichtenstein, J.K. Lue, 2017

机译：普拉拉替纳替克萨斯加罗肽的1阶段研究显示了复发或难治性（R / R）外周T细胞淋巴瘤（PTCL）的患者中显着的活性

Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies

著录项

相似文献

相关主题

期刊订阅